HealthRX.com Reviewed (2026) — $99 Semaglutide, Manifest Pharmacy & the Apothecary Model Tested

HealthRX.com's structural position in the 2026 U.S. telehealth GLP-1 weight-loss category is editorially distinctive in one specific dimension: it publishes more substantive third-party-verifiable disclosure than any other platform in our 14-platform 2026 review set. The named compounding pharmacy partner (Manifest Pharmacy, Greer SC, Section 503A & USP-797 sterile standards, lot-tracked from bench to door) is one of only two named-pharmacy disclosures we've documented in the set — ReflexMD's PCAB+ACHC-accredited pharmacy partner disclosure is the other comparable signal. The named MD Integrations provider network with explicit "they make every clinical decision; HealthRX.com does not employ them" framing is editorially unusual — most platforms describe providers generically as "board-certified U.S. physicians" without disclosing which network actually employs the doctors. The published FDA black-box contraindication list on the homepage — listed before any consultation, with personal-MTC-or-MEN-2-history, MEN-2 syndrome, severe pancreatitis, pregnancy, severe GI disease, and under-18 enumerated explicitly — is a level of editorial honesty rare in the category. And the "What happens when you stop" weight-regain disclosure section — citing STEP-1 Extension (two-thirds of lost weight returns within 12 months of discontinuation), ASBP 2024 (maintenance dosing research), and SURMOUNT-3 lifestyle arm (lifestyle reinforcement holds) — is editorially the most honest GLP-1 post-discontinuation disclosure we've encountered in U.S. telehealth.

The "apothecary" model — what it actually means

HealthRX.com explicitly positions itself as a compounding apothecary marketplace, not a medical practice. Per the published footer:

"HealthRX.com operates as a marketplace platform that connects patients with independently licensed healthcare providers who deliver medical care through the HealthRX.com Patient Portal. HealthRX.com does not directly dispense medication or provide medical services; all clinical decisions are solely made by independent providers. Payment does not guarantee that a prescription will be issued or that medication will be dispensed."

Editorially, this matters. The U.S. telehealth GLP-1 category routinely blurs the line between "we are a medical practice" and "we are a marketplace connecting you to medical practitioners." HealthRX.com's explicit framing — "We compound, dispense, and ship the prescription your provider writes. We don't practice medicine. We don't own the doctor. We don't hide the price." — is structurally distinct from competitors who present themselves as integrated medical practices. For buyers who want clear separation between the platform's commercial interests and the clinical decision-maker, this editorial framing is meaningful.

HealthRX.com pricing in 2026

HealthRX.com publishes two transparent compounded GLP-1 tiers — $99/month compounded semaglutide and $149/month compounded tirzepatide. Here's how that positions HealthRX.com in our 14-platform 2026 review set:

What the published price actually includes

At $99/month (semaglutide) or $149/month (tirzepatide), HealthRX.com includes: compounded medication prepared by Manifest Pharmacy under Section 503A & USP-797 sterile standards, lot-tracked from bench to door; provider review and prescription via MD Integrations within 24 hours; free overnight shipping in all 50 states; HSA/FSA eligibility; HIPAA compliance; 30-day money-back guarantee; one-click cancellation with refund of any unshipped doses. No membership fees, no hidden fees, no insurance billed.

Manifest Pharmacy (Greer, SC) — why naming the pharmacy matters

HealthRX.com names its compounding pharmacy partner publicly: Manifest Pharmacy in Greer, South Carolina, operating under Section 503A of the FD&C Act and USP-797 sterile compounding standards. Every HealthRX.com prescription is compounded at Manifest Pharmacy and lot-tracked from the compounding bench to the patient's door.

Editorially, this matters because for compounded GLP-1 medications, the compounding pharmacy IS the manufacturing controls layer. The compounded semaglutide and tirzepatide arriving at your door aren't manufactured by Novo Nordisk or Eli Lilly — they're prepared by a specific U.S. licensed compounding pharmacy. Naming that pharmacy publicly lets buyers:

• Independently verify the pharmacy's state licensure with the South Carolina Board of Pharmacy.
• Verify the 503A vs 503B designation — Section 503A pharmacies compound patient-specific prescriptions; 503B outsourcing facilities compound in larger quantities under additional FDA registration.
• Verify USP-797 sterile compounding compliance — the published standard for sterile preparations.
• Cross-reference inspection history via state and federal regulatory databases.

Of the 18 platforms we've reviewed in our 2026 set, only HealthRX.com (Manifest Pharmacy) and ReflexMD (PCAB+ACHC-accredited partners) publicly name and disclose their specific compounding pharmacy partners with verifiable accreditation references. Most platforms reference "regulated and certified U.S. pharmacies" generically.

MD Integrations — the named provider network

HealthRX.com names its provider network publicly: MD Integrations. Per HealthRX.com's published FAQ disclosure:

"Who actually writes my prescription? An independent, US-licensed clinician through the MD Integrations provider network. They are licensed in your state. They make every clinical decision. HealthRX.com does not employ them and does not influence the prescribing decision."

MD Integrations is a named, publicly searchable provider-network operator (mdintegrations.com). Naming the specific clinical-decision-maker network — and explicitly separating it from the commercial platform — is editorially distinctive in a category where most platforms describe their providers generically as "board-certified U.S. physicians" without naming the actual employer of the prescribing clinician.

Medications HealthRX.com offers

HealthRX.com's medication menu is intentionally narrow — two core compounded GLP-1 therapies, with explicit editorial focus on quality and disclosure rather than breadth:

• Compounded Semaglutide — From $99/month. Once-weekly subcutaneous injection. Same active ingredient as Wegovy and Ozempic. The most-studied GLP-1 compound. Average 15% body-weight loss at 68 weeks in the STEP-1 trial (HealthRX.com appropriately cites the underlying clinical reference).
• Compounded Tirzepatide — From $149/month. Once-weekly dual-incretin injection. Same active ingredient as Zepbound and Mounjaro. Average 21% body-weight loss at 72 weeks in the pivotal phase-3 trial (HealthRX.com appropriately cites the underlying clinical reference, aligned with SURMOUNT-1 findings).

Note: HealthRX.com does not offer FDA-approved branded medications (Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda) on its platform. If you want branded options on the same platform, see JRNYS (5 branded), Measured (Wegovy Pill + Wegovy + Zepbound), Helimeds (Wegovy + Zepbound), or FuturHealth (5 branded).

Are HealthRX.com medications compounded or FDA-approved?

HealthRX.com is exclusively compounded — both core products are prepared by Manifest Pharmacy under Section 503A. Compounded medications are not individually FDA-approved as finished drug products (category-wide caveat). HealthRX.com's published disclosure is editorially appropriate:

"Compounded medications are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. They are prepared by licensed compounding pharmacies in compliance with Section 503A of the Federal Food, Drug, and Cosmetic Act, based on a valid patient-specific prescription from a licensed healthcare provider."

Published contraindications — the editorial signal

HealthRX.com publishes the full FDA black-box contraindication list directly on its homepage, before any consultation:

1. Personal or family history of medullary thyroid carcinoma
2. Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)
3. History of severe pancreatitis
4. Currently pregnant, planning to become pregnant, or breastfeeding
5. Severe gastrointestinal disease (gastroparesis, severe IBD)
6. Under 18 years of age

This is editorially distinctive. Most platforms in our 2026 review set either bury contraindications inside an intake-flow form (so the patient encounters them only after starting the intake and providing health information) or list them only on a separately-linked safety page. HealthRX.com publishes them on the homepage itself, before any intake — explicit upfront disclosure that gives buyers the option to self-screen out without sharing health data.

"What happens when you stop" — the rarest disclosure in the category

This section, published on HealthRX.com's homepage, is editorially the most honest GLP-1 post-discontinuation disclosure we've encountered in U.S. telehealth:

• "Most people return some weight." Roughly two-thirds of lost weight returns within 12 months of discontinuing semaglutide in published STEP-1 Extension data. "This is the body's setpoint reasserting itself, not a moral failure."
• "Maintenance dosing is real." Obesity medicine is researching maintenance protocols: lower weekly dose, every-other-week, seasonal cycling — per ASBP 2024 reference framing.
• "Lifestyle reinforcement holds." Patients who pair the compound with structural behavior change — protein-prioritized eating, resistance training, sleep — retain more loss after taper, per the SURMOUNT-3 lifestyle arm.

Editorially, this is the answer to the most-asked question in obesity medicine — and most platforms simply don't surface it pre-consultation. HealthRX.com publishes it on the homepage with appropriate clinical references. For buyers who want to understand what they're committing to before they pay, this is the single most editorially honest disclosure section we've encountered in our review set.

Who HealthRX.com is best for

HealthRX.com is a strong fit if you:

• Value the strongest editorial disclosure stack in our 14-platform 2026 review set — named pharmacy, named provider network, published contraindications, honest weight-regain section
• Want $99/month compounded semaglutide (ties bmiMD for #2 cheapest published)
• Want $149/month compounded tirzepatide (ties Helimeds for #1 cheapest published tirzepatide)
• Appreciate the "apothecary marketplace" editorial framing that separates platform commerce from clinical decision-making
• Want full LegitScript certification (Cert. 50087439)
• Need one-click cancellation with unshipped-dose refunds
• Want a 30-day money-back satisfaction guarantee
• Need free overnight shipping in all 50 states
• Value HIPAA + HSA/FSA + named WY corporate HQ + published phone trust signals

HealthRX.com is not the best fit if you:

• Need the absolute lowest published starting price (JRNYS at $89/mo beats HealthRX.com by $10/mo)
• Want FDA-approved branded medications on the same platform — HealthRX.com is compounded-only
• Want active insurance prior-authorization handling (see Measured)
• Want a concrete money-back weight-loss outcome guarantee beyond 30-day satisfaction (see Clinic Secret's 6/12-month tiered guarantee)
• Are pregnant, nursing, under 18, or have GLP-1 contraindications

Real-world HealthRX.com patient feedback

HealthRX.com displays a 4.8 / 5 rating from 12,000+ members with an average member loss of 32 lbs in 9 months. Six named patient stories are published with weight-loss amounts and time-on-program data (Sarah K. -42 lbs / 9 mo; Marcus T. -28 lbs / 6 mo; Lena J. -51 lbs / 12 mo; Dave R. -19 lbs / 4 mo; Priya N. -34 lbs / 8 mo; Caleb W. -24 lbs / 5 mo).

Editorially material: HealthRX.com explicitly discloses its review methodology — "Member reviews shown above are illustrative composites built from anonymized intake-to-outcome data; identifying details have been altered. Individual results vary." This level of transparency is unusual in the category. Most platforms display testimonials as if they were literal individual statements; HealthRX.com publishes the aggregation methodology directly. The underlying 32-lb-in-9-month outcome aggregate is aligned with the STEP-1 (15% body-weight loss at 68 weeks) and SURMOUNT-1 (21% body-weight loss at 72 weeks) trial benchmarks.

"We compound, dispense, and ship the prescription your provider writes. We don't practice medicine. We don't own the doctor. We don't hide the price." — HealthRX.com's published footer framing is the clearest editorial separation between commercial platform and clinical decision-maker we've encountered in U.S. telehealth GLP-1.— Bartley Editorial Analysis

HealthRX.com vs alternatives

HealthRX.com is the only platform in our 14-platform 2026 review set that simultaneously publishes: (a) competitive pricing ties for both semaglutide and tirzepatide, (b) named compounding pharmacy with verifiable Section 503A & USP-797 sterile standards, (c) named provider network with explicit "the doctor makes every decision" framing, (d) full FDA black-box contraindication list on the homepage before consultation, and (e) honest weight-regain disclosure citing STEP-1 Extension, ASBP 2024, and SURMOUNT-3 references. That combination is structurally distinctive — and the editorial reason this review settles at 4.6/5, tying JRNYS for the highest rating in our 2026 set.

HealthRX.com pros and cons

HealthRX.com sign-up & ongoing-care checklists

HealthRX.com frequently asked questions

Honest verdict — should you choose HealthRX.com?

HealthRX.com earns its 4.6/5 editor's rating — tying JRNYS for the highest rating in our 14-platform 2026 review set — on a structurally distinctive editorial transparency stack. The named compounding pharmacy partner (Manifest Pharmacy, Greer SC, Section 503A & USP-797 sterile standards, lot-tracked from bench to door) is rare disclosure in our category. The named MD Integrations provider network with explicit "they make every clinical decision; HealthRX.com does not employ them" framing is editorially distinctive — most platforms describe providers generically without naming the actual employer of the prescribing clinician. The published FDA black-box contraindication list on the homepage before any consultation is editorially honest pre-screening. And the "What happens when you stop" weight-regain disclosure section — citing STEP-1 Extension, ASBP 2024, and SURMOUNT-3 references — is the most editorially honest GLP-1 post-discontinuation disclosure we've encountered in U.S. telehealth.

What pulls the rating just to 4.6 (not higher) is straightforward: $99 starting price ties bmiMD but doesn't beat JRNYS's $89 floor, and FDA-approved branded medications (Wegovy, Ozempic, Mounjaro, Zepbound) aren't offered. The Est. 2024 brand timeline is also shorter than some 100K+ member platforms in our review set. None of these are fatal — they're practical trade-offs of a compounded-only apothecary platform that prices transparency, editorial honesty, and pharmacy-provider disclosure into the program rather than competing purely on the absolute price floor or medication menu breadth.

The bottom line

If you value editorial transparency — named pharmacy with USP-797 sterile standards, named provider network, published contraindications upfront, honest weight-regain disclosure, one-click cancellation, transparent review methodology — HealthRX.com is genuinely the strongest single-platform disclosure stack in our 14-platform 2026 review set. If you prioritize the absolute lowest published cost, JRNYS at $89 beats HealthRX.com's $99 by $10/mo (but doesn't name its compounding pharmacy or provider network). If you need FDA-approved branded medications on the same platform, HealthRX.com isn't a fit — see JRNYS, Measured, Helimeds, or FuturHealth. If you want a concrete money-back weight-loss outcome guarantee beyond HealthRX.com's 30-day satisfaction promise, Clinic Secret's 6/12-month tiered structure is materially different.

Published: June 3, 2026 · Last updated: June 3, 2026 · Verified: June 2026 · Spot a factual issue? Tell our editors.